The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2022 | Treosulfan + fludarabine vs busulfan + fludarabine in active AML post-alloHSCT
Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, discusses the results of a study comparing treosulfan + fludarabine versus busulfan + fludarabine in patients with active acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (alloHSCT). Prior to this, other studies had shown that the treosulfan + fludarabine combination was favored in high-risk patients. Dr Gavriilaki explains that this study demonstrated a clear advantage in overall survival (OS) in patients treated with this combination, suggesting it as the best available option to treat this high-risk population. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Dr Gavriilaki has served as a consultant and/or received honoraria from Alexion Pharmaceuticals, Omeros Corporation, and Sanofi. Dr Gavriilaki has received research support from Jazz Pharmaceuticals.
